GGrantIndex
← Leaderboards

Eric J Small

University Of California, San Francisco

$8,436,342
Attributed
$8,436,342
Total exposure
9
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $5.9M · FY200525
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$12,900,876 · 10

By mechanism

P30$6,663,033 · 4
P50$5,710,129 · 3
R01$511,714 · 1
M01$16,000 · 2

Top collaborators

Most similar at University Of California, San Francisco

Same institution · by research overlap

Others in their field

Top investigators on “Programs

Research focus

ProgramsMalignant Neoplasm Of ProstateCancer Center Support GrantMolecularPeer ReviewCancer PatientBiologicalPublicationsBiological MarkersTumor ProgressionCarcinogenesisFundingMissionMortalityMorbidity - Disease RateDisease ProgressionGenetic TranscriptionBasic ScienceResearch PersonnelClinical TrialsOutcome PredictionOvertreatmentDirect CostsPopulation Sciences

Grant awards (26)

Shared Resource Management$2,745,700
P30 · FY2025 · CA · contact PI
UCSF Specialized Programs of Research Excellence (SPOREs) in Prostate Cancer$2,260,376
P50 · FY2025 · CA · contact PI
Project 2 - Investigating Clinical and Biological Implications of a Novel Hypermethylated Subtype of Metastatic Castration Resistant Prostate Cancer (mCRPC)$528,915
P50 · FY2025 · CA · contact PI
Administrative Core$205,000
P50 · FY2025 · CA · contact PI
Prostate Cancer Program$185,525
P30 · FY2025 · CA · contact PI
Shared Resource Management$2,711,998
P30 · FY2024 · CA · contact PI
UCSF Specialized Programs of Research Excellence (SPOREs) in Prostate Cancer$2,204,158
P50 · FY2024 · CA · contact PI
Project 2 - Investigating Clinical and Biological Implications of a Novel Hypermethylated Subtype of Metastatic Castration Resistant Prostate Cancer (mCRPC)$511,680
P50 · FY2024 · CA · contact PI
Prostate Cancer Program$183,249
P30 · FY2023 · CA · contact PI
Prostate Cancer Program$87,279
P30 · FY2022 · CA · contact PI
Prostate Cancer Program$122,428
P30 · FY2021 · CA · contact PI
Prostate Cancer Program$79,592
P30 · FY2020 · CA · contact PI
Prostate Cancer Program$86,716
P30 · FY2019 · CA · contact PI
Prostate Cancer Program$86,469
P30 · FY2018 · CA · contact PI
Prostate Cancer Program$10,742
P30 · FY2018 · CA · contact PI
Prostate Cancer Program$8,603
P30 · FY2018 · CA · contact PI
Prostate Cancer Program$3,500
P30 · FY2018 · CA · contact PI
Predictive Markers in Metastatic Renal Cancer$511,714
R01 · FY2012 · CA · contact PI
PROSTATE CANCER PROGRAM$69,688
P30 · FY2011 · CA · contact PI
PROSTATE CANCER PROGRAM$70,562
P30 · FY2010 · CA · contact PI
PROSTATE CANCER PROGRAM$71,725
P30 · FY2009 · CA · contact PI
PROSTATE CANCER PROGRAM$74,362
P30 · FY2008 · CA · contact PI
PROSTATE CANCER PROGRAM$64,895
P30 · FY2007 · CA · contact PI
EFFECTS OF BICALUTAMIDE MONOTHERAPY ON BONE DENSITY IN PROSTATE CANCER$4,676
M01 · FY2005 · RR
04557: A PHASE I/II STUDY OF DOCETAXEL/PREDNISONE AND PTK 787/ZK 222584 IN PR$2,806
M01 · FY2005 · RR
Effects of Bicalutamide Monotherapy on Bone Density in Prostate Cancer$8,518
M01 · FY2004 · RR